News

  • 20 September 2019

    FDA grants RMAT designation to SanBio’s cell therapy

    The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to SanBio Group’s cell therapy, SB623, to treat chronic neurological motor deficits secondary to traumatic...

  • 20 September 2019

    NICE recommends Takeda’s Takhzyro in hereditary angioedema

    The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended the use of subcutaneous injection of Takeda’s Takhzyro (lanadelumab) to prevent recurrent attacks of hereditary angioedema (HAE).

Close
Close
Close

Go Top